Related resources
Full-text held externally
Search for item elsewhere
University researcher(s)
Antiangiogenic drugs in ovarian cancer.
Kumaran GC, Jayson GC, Clamp AR
Br J Cancer. 2009;100(1):1-7.
Access to files
Full-text and supplementary files are not available from Manchester eScholar. Full-text is available externally using the following links:
Full-text held externally
Abstract
Ovarian cancer continues to be a major cause of morbidity and mortality in women. Antiangiogenic treatments have emerged as a promising strategy to treat ovarian cancer. This article reviews the rationale supporting the use of antiangiogenic treatments in ovarian cancer, the clinical development of this group of drugs and the toxicities specific to this modality of treatment.
Keyword(s)
Female; Humans; adverse effects: Antibodies, Monoclonal; antagonists & inhibitors: Receptors, Vascular Endothelial Growth Factor; antagonists & inhibitors: Vascular Endothelial Growth Factor A; blood supply: Ovarian Neoplasms; blood supply: Ovary; drug effects: Endothelial Cells; drug therapy: Neovascularization, Pathologic; therapeutic use: Angiogenesis Inhibitors